Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 49 - Preparations for testing in vivo
Patents for A61K 49 - Preparations for testing in vivo (35,376)
11/2003
11/19/2003CN1128167C Nanometer microball of chitosan-polyacrylic acid composite and its producing method and use
11/18/2003US6649366 Methods and compositions related to modulators of annexin and cartilage homeostasis
11/18/2003US6649144 Selectively marking the mitochondria of cancer cells
11/16/2003CA2418229A1 Microbubble construct for sensitivity enhanced mr manometry
11/13/2003WO2003093284A1 Polymetallic molecular complexes used as contrast agents in magnetic image resonance
11/13/2003WO2003093274A1 Camptothecin-taxoid conjugates as antimitotic and antitumor agents
11/13/2003WO2003092737A1 Fusions of cytokines and tumor targeting proteins
11/13/2003WO2003092685A1 USE OF PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) IN THE DIAGNOSIS AND TREATMENT OF CHRONIC LUNG DISEASE AND OTHER PATHOLOGIES
11/13/2003WO2003092590A2 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
11/13/2003WO2003070174A3 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
11/13/2003WO2003068185A3 Use of buckysome or carbon nanotube for drug delivery
11/13/2003WO2003033654A3 Direct targeting binding proteins
11/13/2003WO2003020262A3 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
11/13/2003WO2003014157A3 Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri)
11/13/2003WO2003011019A3 Lethal mouse model for testing of pharmaceuticals and vaccines against neospororis
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003US20030212323 Method of magnetic resonance investigation of a sample using a nuclear spin polarised MR imaging agent
11/13/2003US20030212003 Cathepsin Y for the development of a medicament for the treatment of pain
11/13/2003US20030211967 Method for selectively inhibiting ghrelin action
11/13/2003US20030211636 Determining dosage of drugs metabolized by cytochrome P450 such as 2-methoxy-5-trifluoromethoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine; antibodies
11/13/2003US20030211541 Using immunological means to identify growth differentiation factor-14 (GDF-14) for treating cell proliferative and immunological disorders; gene expression inhibition; antiproliferative agents
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211165 Anticancer agents; mixture of hydrophilic, crosslinked polymer and drugs
11/13/2003US20030211109 Methods of modulating angiogenesis
11/13/2003US20030211043 Staining tear film with dye; monitoring, calibration
11/13/2003US20030211042 Measuring stomach discharging; analyzing emisison in breath; calibration
11/13/2003US20030211036 Method and apparatus for monitoring and quantitatively evaluating tumor perfusion
11/13/2003CA2484425A1 Fusions of cytokines and tumor targeting proteins
11/12/2003EP1361456A2 Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent
11/12/2003EP1359872A2 Vertebroplasty injection device and bone cement therefor
11/12/2003EP1246830B1 Macrocyclic chelants for metallopharmaceuticals
11/12/2003EP0927048B1 Marker compositions
11/12/2003EP0898574B1 Fluorescent chelates as visual tissue specific imaging agents
11/12/2003CN1455873A MRI method involving the use of a hyperpolarized contrast agent
11/12/2003CN1455872A Method of magnetic resonance investigation of sample using nuclear spin polarised MR imaging agent
11/12/2003CN1455686A Hydrophilic, lubricious medical devices having contrast for magnetic resonance imaging
11/11/2003US6645464 Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
11/11/2003US6645463 Blood-pool selective carrier for lipophilic imaging agents
11/11/2003US6645167 Methods for embolizing vascular sites with an embolizing composition
11/06/2003WO2003091729A1 Bio-spectral imaging system and methods for diagnosing cell disease state
11/06/2003WO2003091696A2 Process for identifying and treating specified cell types
11/06/2003WO2003091694A2 Method for assay of cognition and memory based on low frequency stimulation
11/06/2003WO2003090604A2 Method of endovascular brain mapping
11/06/2003WO2003090599A2 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
11/06/2003WO2003090529A2 Methods for identifying and using insecticides
11/06/2003WO2003062198A8 Integrin targeted imaging agents
11/06/2003WO2003057007A3 System for monitoring bacterial tumor treatment
11/06/2003WO2003034975A3 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
11/06/2003WO2003032901A3 Pathological tissue detection and treatment employing targeted benzoindole optical agents
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003009804A3 Conformationally constrained parathyroid hormone (pth) analogs
11/06/2003WO2002083854A9 Antibodies to vla-1
11/06/2003WO2002080960A3 Treatment of neuropathologies associated with expression of tnf-alpha
11/06/2003WO2002059312A3 Cell adhesion proteins
11/06/2003US20030207823 Novel diabetes imaging probes
11/06/2003US20030207469 Via immunoassay; low cross-reactivity with ephedrine and other compounds; antibody produced by a methylene dioxyphenyl derivative of agiven structure
11/06/2003US20030207447 Used to distinguish between arterial endothelial cells (arteries) and venous endothelial cells (veins)
11/06/2003US20030207330 Fibrinogen binding moieties
11/06/2003US20030206865 Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy
11/06/2003US20030206864 Embolic agents visible under ultrasound
11/06/2003US20030206863 Methods of resonance imaging using ultrasonic energy
11/06/2003US20030206862 Contrast medium based on polyoxyethylene-660-12-hydroxystearate and anionic phospholipids
11/06/2003US20030206859 Nanometer-sized carrier medium
11/06/2003US20030206858 Metal complex-containing pharmaceutical agents
11/06/2003CA2483635A1 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
11/06/2003CA2483420A1 Bio-spectral imaging system and methods for diagnosing cell disease state
11/05/2003EP1358330A2 Transporters and ion channels
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1357971A2 Regulation of eating habits
11/05/2003EP0814847B1 Methods and compositions for in-vivo detection of oral cancers and precancerous conditions
11/04/2003US6641798 Tumor-targeted optical contrast agents
11/04/2003CA2123570C Cocaine receptor binding ligands
10/2003
10/30/2003WO2003089928A1 Test for measurement of therapeutic drug levels
10/30/2003WO2003089898A2 Determining biochemical markers of progression and therapy monitoring and specification, therapeutic lead molecules, and target biochemical systems applied to stroke
10/30/2003WO2003089657A1 Method for phenotyping using nmr spectroscopy
10/30/2003WO2003089438A1 Labeled oxazinocarbazoles as diagnostic agents
10/30/2003WO2003089013A1 Cyclooxygenase-2 selective agents useful as imaging probes and related methods
10/30/2003WO2003089012A2 Cavity filling biopsy site marker
10/30/2003WO2003089009A1 Microparticles comprising carbohydrate beads covalently linked with allergen
10/30/2003WO2003088913A2 Peptide deformylase activated prodrugs
10/30/2003WO2003088904A2 Screening and therapeutic methods for treating circadian rhythm disorders
10/30/2003WO2003088823A2 Novel macrocyclic activatible magnetic resonance imaging contrast agents
10/30/2003WO2003031568A3 Intracellular signaling molecules
10/30/2003WO2003031452A3 4-haloethenylphenyl tropane:serotonin transporter imaging agents
10/30/2003WO2003029482A3 Diagnosing, treating, and preventing cancer using cables
10/30/2003WO2003028527A3 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
10/30/2003WO2003020320A3 Nanoparticles comprising biologically active tnf which is immobilised on the same
10/30/2003WO2003016549A3 Nucleic-acid associated proteins
10/30/2003WO2002102239A3 Method of early detection of duchenne muscular dystrophy and other neuromuscular disease
10/30/2003WO2002059283A3 Nucleic acid modification enzymes
10/30/2003WO2002054088A3 Contrast enhancement agent for magnetic resonance imaging
10/30/2003WO2001097794A8 Inhibitors of matriptase for the treatment of cancer
10/30/2003US20030204859 Animal model of polyglutamine toxicity, methods of use, and modulators of polyglutamine toxicity
10/30/2003US20030203888 Chromophores
10/30/2003US20030203880 Such as methyl-5-aminolevulinate hydrochloride; porphyrins; antitumor agents; anticancer agents
10/30/2003US20030203879 For enhancing magnetic resonance imaging (MRI); nuclear magnetic resonance
10/30/2003US20030202943 Nuclear magnetic resonance; medical diagnosis; diethylenetriaminepentaacetic acid monoamide
10/30/2003US20030202942 Membrane forming lipid containing contrast agent; medical diagnosis
10/30/2003US20030202941 Absorption, fluorescence; using light for optical medical diagnosis
1 ... 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 ... 354